Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of RYMPHYSIA in A1PI Deficiency with COPD-Emphysema
NCT05466747Phase 4Withdrawn
- Sponsor
- Takeda
- Start
- Jan 2024
- Primary completion
- Apr 2027
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 4 trial of alpha-1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD), pulmonary emphysema, sponsored by Takeda. Planned start Jan 2024; status: withdrawn.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)pulmonary emphysema
Beyond the preview
Go deeper on NCT05466747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05466747.